 Stacey Martiniano
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 37 | 2026 | 1158 | 7.400 |
Why?
| | Mycobacterium Infections, Nontuberculous | 17 | 2025 | 366 | 4.630 |
Why?
| | Nontuberculous Mycobacteria | 11 | 2023 | 208 | 3.120 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 6 | 2026 | 370 | 1.330 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 63 | 1.180 |
Why?
| | Neonatal Screening | 4 | 2023 | 178 | 0.970 |
Why?
| | Ethambutol | 1 | 2021 | 27 | 0.680 |
Why?
| | Rifampin | 1 | 2021 | 82 | 0.660 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.650 |
Why?
| | Mycobacterium abscessus | 4 | 2025 | 118 | 0.650 |
Why?
| | Azithromycin | 1 | 2021 | 104 | 0.640 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 324 | 0.600 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 88 | 0.590 |
Why?
| | Sputum | 3 | 2020 | 308 | 0.570 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 175 | 0.570 |
Why?
| | Genetic Testing | 1 | 2021 | 478 | 0.560 |
Why?
| | Clofazimine | 1 | 2017 | 15 | 0.520 |
Why?
| | Algorithms | 2 | 2021 | 1837 | 0.490 |
Why?
| | Aminophenols | 4 | 2026 | 201 | 0.490 |
Why?
| | Meconium Ileus | 2 | 2026 | 12 | 0.450 |
Why?
| | Coinfection | 4 | 2020 | 141 | 0.440 |
Why?
| | Humans | 39 | 2026 | 144759 | 0.390 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 131 | 0.380 |
Why?
| | Mutation | 5 | 2023 | 4089 | 0.350 |
Why?
| | Quinolones | 4 | 2026 | 201 | 0.350 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.350 |
Why?
| | Pneumonia | 1 | 2017 | 631 | 0.340 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 370 | 0.310 |
Why?
| | Disease Management | 1 | 2014 | 645 | 0.310 |
Why?
| | Pyrazoles | 2 | 2024 | 509 | 0.310 |
Why?
| | Lung Diseases | 1 | 2016 | 787 | 0.310 |
Why?
| | Indoles | 2 | 2024 | 501 | 0.300 |
Why?
| | Pyridines | 2 | 2024 | 605 | 0.300 |
Why?
| | Infant, Newborn | 6 | 2024 | 6429 | 0.290 |
Why?
| | Retrospective Studies | 9 | 2022 | 17066 | 0.290 |
Why?
| | Pseudomonas aeruginosa | 3 | 2021 | 356 | 0.260 |
Why?
| | Morbidity | 2 | 2019 | 323 | 0.240 |
Why?
| | Pyrrolidines | 2 | 2024 | 125 | 0.230 |
Why?
| | Phage Therapy | 1 | 2025 | 17 | 0.220 |
Why?
| | Child | 8 | 2022 | 22633 | 0.220 |
Why?
| | Benzodioxoles | 2 | 2024 | 158 | 0.210 |
Why?
| | Leprostatic Agents | 1 | 2022 | 6 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2024 | 191 | 0.190 |
Why?
| | Delayed Diagnosis | 1 | 2023 | 95 | 0.190 |
Why?
| | Infant | 5 | 2023 | 10034 | 0.180 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.180 |
Why?
| | Trypsinogen | 1 | 2021 | 11 | 0.180 |
Why?
| | Quality Improvement | 3 | 2020 | 1289 | 0.170 |
Why?
| | Adolescent | 7 | 2021 | 22428 | 0.170 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.170 |
Why?
| | Cohort Studies | 4 | 2022 | 5960 | 0.170 |
Why?
| | Oropharynx | 1 | 2021 | 46 | 0.170 |
Why?
| | Chloride Channel Agonists | 2 | 2024 | 109 | 0.170 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.160 |
Why?
| | Bacteriophages | 1 | 2022 | 111 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1047 | 0.150 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 372 | 0.150 |
Why?
| | Specimen Handling | 1 | 2021 | 186 | 0.150 |
Why?
| | Antitubercular Agents | 1 | 2021 | 215 | 0.150 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 334 | 0.150 |
Why?
| | Cross-Over Studies | 1 | 2021 | 601 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 108 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2025 | 11679 | 0.140 |
Why?
| | Respiratory Function Tests | 1 | 2020 | 547 | 0.140 |
Why?
| | Infection Control | 1 | 2019 | 172 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1053 | 0.130 |
Why?
| | Risk Factors | 4 | 2019 | 10779 | 0.130 |
Why?
| | Cross Infection | 1 | 2019 | 262 | 0.130 |
Why?
| | Lipopolysaccharides | 1 | 2020 | 863 | 0.120 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1907 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1985 | 0.120 |
Why?
| | United States | 5 | 2021 | 15966 | 0.120 |
Why?
| | Anti-Infective Agents | 1 | 2019 | 242 | 0.120 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 171 | 0.120 |
Why?
| | Anticoagulants | 1 | 2021 | 722 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 397 | 0.100 |
Why?
| | Genotyping Techniques | 1 | 2014 | 69 | 0.100 |
Why?
| | Genetic Therapy | 1 | 2016 | 313 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 474 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 331 | 0.100 |
Why?
| | Male | 9 | 2025 | 72315 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 406 | 0.100 |
Why?
| | Female | 9 | 2026 | 78271 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2027 | 0.090 |
Why?
| | Prospective Studies | 2 | 2025 | 7990 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 85 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2020 | 3604 | 0.090 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 449 | 0.090 |
Why?
| | Young Adult | 4 | 2020 | 14105 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 401 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2385 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 975 | 0.090 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 221 | 0.090 |
Why?
| | Prevalence | 1 | 2019 | 2834 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 116 | 0.090 |
Why?
| | Child, Preschool | 3 | 2021 | 11787 | 0.090 |
Why?
| | Genotype | 1 | 2016 | 1833 | 0.080 |
Why?
| | Adult | 6 | 2025 | 40449 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 181 | 0.080 |
Why?
| | Disease Progression | 1 | 2016 | 2847 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5408 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2583 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 834 | 0.060 |
Why?
| | Animals | 2 | 2019 | 38058 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8265 | 0.050 |
Why?
| | Lung | 3 | 2022 | 4109 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 405 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 390 | 0.050 |
Why?
| | Quinolines | 1 | 2024 | 193 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Pregnancy | 2 | 2026 | 7190 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 25 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2023 | 284 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 316 | 0.040 |
Why?
| | Middle Aged | 2 | 2020 | 35875 | 0.040 |
Why?
| | Neutrophils | 1 | 2023 | 1134 | 0.030 |
Why?
| | Aged | 1 | 2017 | 25913 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2115 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1886 | 0.030 |
Why?
| | Superoxides | 1 | 2013 | 204 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2879 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 278 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4271 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1782 | 0.010 |
Why?
|
|
Martiniano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|